Literature DB >> 33850228

In vitro evaluation of simulated stereotactic radiotherapy for wet age-related macular degeneration on three different cell lines.

Efstathios Vounotrypidis1,2, Anna Hillenmayer3,4, Christian M Wertheimer3,4, Alexis Athanasiou4, Jakob Siedlecki4, Michael Orth5, Andreas Ohlmann4, Siegfried G Priglinger4, Armin Wolf3,4.   

Abstract

Low energy stereotactic radiotherapy has been proposed for the treatment of neovascular age related macular degeneration. We investigated the in vitro effect of the radiotherapy on pericytes, retinal pigment epithelium and endothelial cells. Primary human retinal pigment epithelium cells, human umbilical vein endothelial cells and human pericytes from Placenta were cultivated. In a pairwise protocol, one plate was irradiated at a dose of 16 Gy, while the second plate served as a non-irradiated control. Thereafter, cells were cultivated either in serum-free (non-permissive) or serum-stimulated (permissive) conditions. A life/dead assay, an XTT and a BrdU assay were performed up to 7 days after irradiation. No cell death occurred at any timepoint in any cell line after treatment nor in the control. Compared to the unirradiated controls, cell viability and metabolic activity were significantly reduced in irradiated cells in the XTT assay, except for non-permissive RPE cells. In the BrdU assay, proliferation was inhibited. While no cell death was detected in vitro, viability and proliferative capacity of all cell lines were significantly reduced. Therefore, it seems that low energy stereotactic radiotherapy inhibits angiogenesis without a direct induction of apoptosis but influencing microvascular function and stability.

Entities:  

Year:  2021        PMID: 33850228     DOI: 10.1038/s41598-021-87466-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  45 in total

1.  Clinicopathological correlation of choroidal neovascularization after external beam radiotherapy in age-related macular degeneration.

Authors:  S Aisenbrey; B A Lafaut; S Reynders; P Szurman; S Grisanti; C Vanden Broecke; P Walter; K U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-22       Impact factor: 3.117

2.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Effect of focal X-ray irradiation on experimental choroidal neovascularization.

Authors:  H Miyamoto; H Kimura; T Yasukawa; Y Honda; Y Tabata; Y Ikada; K Sasai; Y Ogura
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-06       Impact factor: 4.799

5.  Low-Energy Stereotactic Radiotherapy for Treatment of Exudative Age-Related Macular Degeneration in a Treat-and-Extend Regimen.

Authors:  Katja Hatz; Frank Zimmermann; Dimitrios Kardamakis; Emmanouil Lazaridis; Cengiz Türksever; Jörg Binder; Alexandros Papachristofilou; Christian Prünte
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2018-02-01       Impact factor: 1.300

6.  Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response.

Authors:  Timothy L Jackson; E Mark Shusterman; Mark Arnoldussen; Erik Chell; Kun Wang; Darius M Moshfeghi
Journal:  Retina       Date:  2015-02       Impact factor: 4.256

7.  Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.

Authors:  Timothy L Jackson; Usha Chakravarthy; Jason S Slakter; Alyson Muldrew; E Mark Shusterman; Denis O'Shaughnessy; Mark Arnoldussen; Michael E Gertner; Linda Danielson; Darius M Moshfeghi
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

8.  [Patient-Reported Treatment Satisfaction with Stereotactic Radiotherapy in Neovascular Age-Related Macular Degeneration].

Authors:  Maximilian Kurz; Martin Rudolf; Annekatrin Holzhey; Aljoscha S Neubauer; Salvatore Grisanti; Mahdy Ranjbar
Journal:  Klin Monbl Augenheilkd       Date:  2017-08-24       Impact factor: 0.700

9.  Radiation therapy for neovascular age-related macular degeneration.

Authors:  Robert Petrarca; Timothy L Jackson
Journal:  Clin Ophthalmol       Date:  2011-01-10

10.  Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.

Authors:  Armin Wolf; Anselm Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-15       Impact factor: 3.117

View more
  1 in total

1.  Pharmacological drug screening to inhibit uveal melanoma metastatic cells either via EGF-R, MAPK, mTOR or PI3K.

Authors:  Stefan Kassumeh; Sebastian Arrow; André Kafka; Nikolaus Luft; Siegfried G Priglinger; Armin Wolf; Kirsten Eibl-Lindner; Christian M Wertheimer
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.